The wearable defibrillator developer revealed GV is an existing investor as it raised more than $145m that will support the launch of its lead product.

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Existing investors Novartis Venture Fund and Partners Innovation Fund chipped in as the hearing loss therapy developer closed its latest round.

Aflac Ventures has invested in cardiac diagnosis system developer Tricog Health as part of a $10.5m round that took its total funding to more than $17m.

Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.

Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.

University of Tokyo Edge Capital has returned to invest in AI-assisted cardiac diagnosis technology developer Tricog Health.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The immuno-oncology therapy developer has raised a sliver over $100m, Takeda Ventures leading a round that included M Ventures, Ipsen Ventures and MRL Ventures Fund.

The university has put together a $1m fund for health-oriented participants in its Velocity accelerator competition.